袁礼;吴焕文;任新瑜;梁智勇;
YUAN Li;WU Huan-wen;REN Xin-yu;LIANG Zhi-yong;Department of Pathology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;

• 1:中国医学科学院 北京协和医学院 北京协和医院病理科

摘要(Abstract)：

目的比较三阴乳腺癌与非三阴乳腺癌在临床病理特征及部分免疫组织化学指标表达上的差异,并探讨这些免疫组织化学指标的表达与三阴乳腺癌临床病理特征及预后的关系。方法 2010年1月至2013年12月北京协和医院收治的经组织病理确诊的乳腺癌患者共863例,其中三阴乳腺癌患者135例,非三阴乳腺癌患者728例。分析三阴乳腺癌与非三阴乳腺癌患者在发病年龄、病理类型、肿瘤大小、分化程度、肿瘤分期、是否有淋巴结转移、是否累及乳头以及手术方式等临床病理特征方面的差异。通过免疫组织化学法检测135例三阴乳腺癌患者与经单纯抽样法选取的135例非三阴乳腺癌患者中雌激素受体β(estrogen receptor β,ERβ)、表皮生长因子受体(epidermal growth factor receptor,EGFR)、P53、Ki67的表达,分析上述指标在两类乳腺癌中的表达差异。进一步通过单因素生存分析探讨三阴乳腺癌患者的预后相关因素。结果三阴乳腺癌中浸润性导管癌的比例高于非三阴乳腺癌(86.7%比65.2%,P<0.001),发病年龄低于非三阴乳腺癌[(46.0±10.6)岁比(51.0±13.3)岁,P<0.05];三阴乳腺癌与非三阴乳腺癌在淋巴结转移、临床分期、肿瘤大小、分化程度、手术方式方面差异亦有统计学意义(P<0.05);三阴乳腺癌与非三阴乳腺癌在肿瘤累及乳头的比例差异无统计学意义(P>0.05)。免疫组织化学结果显示,三阴乳腺癌中ERβ阳性表达率较非三阴乳腺癌显著降低(63.7%比75.6%,P<0.05),而EGFR阳性表达率显著升高(62.2%比33.3%,P<0.05);P53、Ki67在三阴乳腺癌与非三阴乳腺癌中的表达差异无统计学意义(P>0.05)。与非三阴乳腺癌相比,三阴乳腺癌的总体生存率(overall survival,OS)和无复发生存率(relapse-free survival,RFS)更低(P<0.05)。三阴乳腺癌单因素生存分析结果显示,ERβ阴性表达与EGFR阳性表达均与三阴乳腺癌的不良预后相关(P<0.05)。结论相较于非三阴乳腺癌,三阴乳腺癌有明显不同的临床病理特征:发病年龄较低、原发肿瘤体积较大、分化程度低、易发生淋巴结转移、ERβ阳性表达率较低、EGFR阳性表达率较高、OS及RFS较低。ERβ和EGFR可能成为重要的三阴乳腺癌预后判断指标。
Objective To analyze the differences in clinicopathologic features and expressions of some immunohistochemical indicators between triple negative breast cancer and non-triple negative breast cancer,and to investigate the relationship between clinicopathological features and immunohistochemical indicators. MethodsA total of 863 patients( 135 triple negative breast cancer and 728 non-triple negative breast cancer) with histopathologically confirmed breast cancer were collected in Peking Union Medical College Hospital from January2010 to December 2013. We retrospectively analyzed the difference in the onset age,histological subtype,tumor size,tumor differentiation,tumor stages,lymph node metastasis,nipple involvement and operation method between triple negative breast cancer and non-triple negative breast cancer,then explored the difference between them in the expressions of estrogen receptor β( ERβ),epidermal growth factor receptor( EGFR),P53,and Ki67 by immunohistochemical staining. Prognostic factors of triple negative breast cancer were further discussed by univariate survival analysis. Results The proportion of invasive ductal carcinoma in triple negative breast cancer was higher than that in non-triple negative breast cancer( 86. 7% vs. 65. 2%,P < 0. 001); the age of onset was younger in triple negative breast cancer [( 46. 0 ± 10. 6) years vs.( 51. 0 ± 3. 3) years,P < 0. 05 ];significant differences were also found in lymph node metastasis,tumor size,differentiation grade,surgical procedure,and tumor stages between the two groups( P < 0. 05); no statistically significant inter-group difference in nipple involvement( P > 0. 05). Immunohistochemical results showed that compared with non-triple negative breast cancer,ERβ expression rate decreased significantly( 63. 7% vs. 75. 6%, P < 0. 05) while EGFR expression rate increased significantly in triple negative breast cancer( 62. 2% vs. 33. 3%,P < 0. 05); the expression of P53 and Ki67 demonstrated no significant difference( P > 0. 05). The overall survival( OS) and relapse-free survival( RFS) were both lower in triple negative breast cancer( P < 0. 05). Univariate survival analysis showed that both ERβ negative expression and EGFR positive expression were related to the poor prognosis of triple negative breast cancer( P < 0. 05). Conclusions Compared with non-triple negative breast cancer,triple negative breast cancer shows completely different clinicopathological features: younger age of onset,larger tumor size,lower degree of differentiation,higher incidence of lymph node metastasis,lower ERβ expression,higher EGFR expression,and lower OS and RFS. ERβ and EGFR may be important prognostic indicators in triple negative breast cancer.

关键词(KeyWords)： 三阴乳腺癌;雌激素受体β;表皮生长因子受体;临床病理特征;预后
triple negative breast cancer;estrogen receptor β;epidermal growth factor receptor;clinicopathological features;prognosis

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 袁礼;吴焕文;任新瑜;梁智勇;
YUAN Li;WU Huan-wen;REN Xin-yu;LIANG Zhi-yong;Department of Pathology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;

参考文献(References)：

• [1]Zheng G,Peng F,Ding R,et al.Identification of proteins responsible for the multiple drug resistance in 5-fluorouracilinduced breast cancer cell using proteomics analysis[J].Cancer Res Clin Oncol,2010,136:1477-1488.
• [2]Perou CM,Softie T,Eisen MB,et al.Molecular portraits of human breast turnouts[J].Nature,2000,406:747-752.
• [3]Strehl JD,Wachter DL,Fasching PA,et al.Invasive breast cancer:recognition of molecular subtypes[J].Breast Care(Basel),2011,6:258-264.
• [4]Dent R,Trudeau M,Pritchard KJ,et al.Triple negative breast cancer:features and patterns of recurrence[J].Clin Cancer Res,2007,13:4429-4434.
• [5]Abkevich V,Timms K,Hennessy B,et al.Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer[J].Br J Cancer,2012,107:1776-1782.
• [6]Van den Akker EB,Verbruggen B,Heijmans BT,et al.Integrating protein-protein interaction networks with gene-gene co-expression networks improves gene signatures for classifying breast cancer metastasis[J].Integr Bioinform,2011,8:188.
• [7]Carey LA,Dees EC,Sawyer L,et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes[J].Clin Cancer Res,2007,13:2329-2334.
• [8]Bauer KR,Brown M,Cress RD,et al.Descriptive analysis of estrogen receptor(ER)-negative,progesterone receptor(PR)-negative,and HER2-negative invasive breast cancer,the so-called triple-negative phenotype:a population-based study from the California cancer Registry[J].Cancer,2007,109:1721-1728.
• [9]Wirapati P,Sotirlou C,Kunkel S,et al.Meta-analysis of gene expression profiles in breast cancer:toward a unified understanding of breast cancer subtyping and prognosis signatures[J].Breast Cancer Res,2008,10:R65.
• [10]Kuiper GG,Enmark E,Pelto-Huikko M,et al.Cloning of a novel receptor expressed in rat prostate and ovary[J].Proc Natl Acad Sci USA,1996,93:5925.
• [11]Cuzick J,Dowsett M,Pineda S,et al.Prognostic value of a combined estrogen receptor,progesterone receptor,Ki-67,and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer[J].J Clin Oncol,2011,29:4273-4278.
• [12]Murphy LC,Leygue E.The role of estrogen receptor-βin breast cancer[J].Semin Reprod Med,2012,30:5-13.
• [13]Murphy LC,Leygue E.A bi-faceted role of estrogen receptorβin breast cancer[J].Endocri Relat Cancer,2013,20:R127-R139.
• [14]Speirs V,Malone C,Walton DS,et al.Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients[J].Cancer Res,1999,59:5421-5424.
• [15]Sugiura H,Toyama T,Hara Y,et al.Expression of estrogen receptorβwild-type and its variant ER-βcx/β2 is correlated with better prognosis in breast cancer[J].Jpn J Clin Oncol,2007,37:820-828.
• [16]Corkery B,Crown J,Clynes M,et al.Epidermal growth factor receptor as a potential therapeutic target in triple negative breast cancer[J].Ann Oncol,2009,20:862-867.
• [17]Ulivi P,Zoli W,Capelli L,et al.Target therapy in NSCLC patients:relevant clinical agents and tumor molecular characterization[J].Mol Clin Oncol,2013,7:575-581.
• [18]Nielsen TO,Hsu FD,Jensen K,et a1.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10:5367-5374.
• [19]Davidoff AM,Herndon JE,Glover NS,et al.Relation between p53 over expression and established prognostic factors in breast cancer[J].Surgery,1991,110:259-264.
• [20]Bhatavdekar JM,Patel DD,Shah NG,et a1.Prognostic significance of immunohistochemically localized biomarkers in stageⅡand stageⅢbreast cancer:a multivariate analysis[J].Ann Surg Oncol,2000,7:305-311.